Ser­vices firm Mesa buys out mol­e­c­u­lar di­ag­nos­tics play­er for a cool $300M as ge­net­ics test­ing gains steam

The rise in ge­net­ic test­ing has spurred a rev­o­lu­tion in drug de­vel­op­ment, and now a bio­phar­ma ser­vices firm is look­ing to jump on board in a big way.

Mesa Lab­o­ra­to­ries will ac­quire Age­na Bio­science, a ge­net­ic di­ag­nos­tics com­pa­ny based out of San Diego, for $300 mil­lion, the com­pa­ny an­nounced Tues­day.

Age­na is ex­pect­ed to reel in be­tween $63 mil­lion and $67 mil­lion in rev­enue in Mesa’s first year of own­er­ship. That num­ber doesn’t in­clude any pos­si­ble Covid-19 rev­enue, which is ex­pect­ed to bring in an­oth­er $3 mil­lion to $5 mil­lion in rev­enue.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER